Quince Therapeutics, Inc.

QNCXSEC EDGAR

Biological Products, (No Diagnostic Substances)(CA)CIK: 1662774

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$9.4M	$25.2M	$60.8M	$30.2M	$10.1M
Operating Expenses	$34.6M	$52.0M	$90.3M	$39.2M	$12.1M
Operating Income (Loss)	-$34.6M	-$52.0M	-$90.3M	-$39.2M	-$12.1M
Interest Expense	—	—	—	—	$957.0K
Other Nonoperating Income (Expense)	-$102.0K	-$997.0K	-$247.0K	$0.00	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$31.6M	-$51.9M	-$89.9M	-$37.0M	—
Income Tax Expense (Benefit)	-$197.0K	-$284.0K	$0.00	—	$0.00
Net Income (Loss) Attributable to Parent	-$31.4M	-$51.7M	-$89.9M	-$37.0M	-$12.5M
Earnings Per Share, Basic	-$0.84	-$1.54	-$3.03	—	—
Earnings Per Share, Diluted	-$0.84	-$1.54	-$3.03	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$167.9M	$103.9M	$133.2M	$189.5M	$124.4M
Assets, Current	$77.4M	$93.7M	$111.7M	$137.9M	$106.1M
Cash and Cash Equivalents, at Carrying Value	—	—	—	—	—
Liabilities	$82.8M	$3.3M	$14.6M	$17.2M	$8.9M
Liabilities, Current	$9.6M	$3.1M	$14.2M	$17.0M	$8.9M
Long-term Debt	$13.4M	$0.00	—	—	—
Accounts Payable, Current	$2.0M	$570.0K	$4.9M	$3.6M	$3.1M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$18.3M	-$44.0M	-$62.9M	-$33.3M	-$11.7M
Net Cash Provided by (Used in) Investing Activities	-$5.8M	$18.0M	$59.0M	-$17.7M	-$46.8M
Net Cash Provided by (Used in) Financing Activities	$143.0K	$707.0K	$6.8M	$77.4M	$75.9M
Payments to Acquire Property, Plant, and Equipment	$160.0K	$133.0K	$180.0K	$55.0K	$212.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)